GREM1 and neoplasm: In 2023, UCB launched a Phase 1/2 clinical trial to assess the safety, pharmacokinetics and anti-tumor activity of the GREM1 neutralizing antibody Ginisortamab (UCB6114) in patients with solid tumors in [81].